Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Pemetrexed Stories

2012-05-16 14:22:22

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012. LUX-Lung 3, which compares the investigational oral, once-daily...

2012-05-14 02:28:13

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 - 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented progression-free...

2012-04-04 20:14:45

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4. Patients, especially those with lung cancer, who have KRAS gene mutations have a worse prognosis and do not respond well to targeted therapies, according to Sarah Bacus, Ph.D.,...

2012-02-17 13:00:00

The Mesothelioma Applied Research Foundation announced its decision to fund five mesothelioma research projects amounting to a total of $500,000 and bringing the Foundation´s overall investment in research to $7.6 million. Washington, D.C. (PRWEB) February 17, 2012 The Mesothelioma Applied Research Foundation (Meso Foundation) announced today the funding of an additional five mesothelioma research projects in an effort to accelerate the search for new and effective treatments and a...

2012-01-17 17:00:00

Jack Clapper is an expert asbestos and mesothelioma attorney and founder of one of the first mesothelioma law firms in California, Clapper Patti Schweizer & Mason (CPSM), which specializes in representing those injured by asbestos. Having been in the field for over three decades, Clapper and his firm not only understands the complexities of asbestos litigation and bankruptcy trust claims, but also the urgent need to provide the most up-to-date information regarding treatments for...

2011-12-02 11:00:00

Last month, the Mesothelioma Applied Research Foundation started a new educational program for mesothelioma patients, their families, and other interested parties. The program consists of teleconference interviews with mesothelioma experts discussing their newest clinical trials and research advances. Washington, DC (PRWEB) December 02, 2011 The Mesothelioma Applied Research Foundation (Meso Foundation) is pleased to report that its â˜Meet the Expertsâ...

2011-11-14 15:23:43

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients. "Our findings indicate that when patients with lung cancer have specific changes in the KRAS gene, they become very amenable to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles senior vice president and chief scientific officer...

2011-10-28 02:00:00

INDIANAPOLIS, Oct. 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer (NSCLC). The approval is based on clinical trial results showing an improvement in progression-free survival, as well as...

2011-10-17 12:57:42

Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer. Researchers did not speculate on the reason for the effect, but said that the survival benefit warranted more study and that diabetes should not be considered a reason to withhold standard cancer treatment. "Standard...

2011-09-26 12:00:00

INDIANAPOLIS, Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that continuation maintenance therapy with ALIMTA(® )(pemetrexed for injection) also reduces the risk of disease progression in patients aged 70 years or older with advanced nonsquamous non-small cell lung cancer (NSCLC), the most common type of lung cancer. Results from the new analysis...